· Published by Health Canada · Official notice
This is duplicated text of a letter from Sandoz Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
December 19, 2013
Dear Health Care Professional;
Subject: Potential for Particulate Matter in 2 mL and 5 mL Vials of Phenytoin Sodium Injection USP 50 mg/mL (DIN: 00780626, Product Codes: 44000553 (6200) and 44000554 (6211))
Sandoz Canada Inc., in consultation with Health Canada, would like to inform you of the possible presence of particulate matter in some vials (2 mL and 5 mL size) of Phenytoin Sodium Injection USP 50 mg/mL. Low levels of sub-visible particulate matter, determined to be inert carbon related to the vial manufacturing process, have been noted during a recent investigation. Particulate matter has not been observed in the listed lots of Phenytoin Sodium Injection USP which have been released onto the Canadian market. Furthermore, the listed lots met all standards for particulate matter (visible and sub-visible) prior to release onto the Canadian market, and those lots monitored on routine stability continue to meet these standards. However, the possible presence of visible particulate matter in these lots cannot be excluded. A list of potentially affected lots is attached (Appendix A).
Phenytoin Sodium Injection USP is indicated for control of tonic-clonic (grand mal) and psychomotor or partial (focal) seizures as well as for the prevention and treatment of seizures occurring during neurosurgery. Phenytoin Sodium Injection USP is approved for direct intravenous injection and for intramuscular administration.Footnote 1
Intravenous treatment should be reserved for use only in those patients who cannot be treated with oral phenytoin. Oral therapy should replace parenteral administration as soon as possible.Footnote 1 Precipitation of free phenytoin may occur at pH 11.5 or less. The mixing of phenytoin sodium with other drugs or with intravenous infusion solutions may result in crystallization or precipitation if the drug product in the vial has been kept in a refrigerator or freezer, or the pH is lowered.Footnote 2
Since the release of the potentially affected lots of Phenytoin Sodium Injection USP, no adverse event reports related to this issue were received at Sandoz Canada Inc. Any Sandoz phenytoin vial with evidence of visible particulates should not be used and should be reported to Sandoz Canada.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious adverse reaction or unexpected adverse reactions in patients receiving Phenytoin Sodium Injection USP should be reported to Sandoz Canada Inc. or Health Canada.
Sandoz Canada Inc,
145 Jules Léger
Boucherville, Quebec, Canada
J4B 7K8
Tel: 1-800-343-8839 ext. 4636
Fax: 1-888-243-6221
To correct your mailing address or fax number, contact Sandoz Canada Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, contact Health Canada at:
Health Products and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636
If you have questions regarding the above information, please contact our Drug Information Department at 1-800-343-8839 (4636).
Sincerely,
original signed by
Michèle Théberge
Vice-President, Quality Unit
original signed by
Len Arsenault
Vice-President, Scientific Affairs
Sandoz Canada Inc., Phenytoin Sodium Injection USP, Prescribing Information, revised April 10, 2013.
Handbook on Injectable Drugs, accessed on 12-Dec-2013
Encl. Appendix A
| Material | Material Description | Batch | Expiry Date |
|---|---|---|---|
| 44000554 | PHENYTOIN NA 50MG/ML 5ML 10LIVI CA | BT9159 | 2013-12-31 |
| CG2519 | 2014-08-31 | ||
| CH9389 | 2014-09-30 | ||
| CK9567 | 2014-10-31 | ||
| CX9724 | 2015-04-30 | ||
| DA2448 | 2015-06-30 | ||
| DE5293 | 2015-08-31 | ||
| 44000553 | PHENYTOIN NA 50MG/ML 2ML 10LIVI CA | BG1193 | 2013-12-31 |
| BL9015 | 2014-03-31 | ||
| CB1255 | 2014-11-30 | ||
| CG0113 | 2015-02-28 | ||
| CJ8539 | 2015-04-30 | ||
| CN3870 | 2015-06-30 | ||
| DA4554 | 2015-12-31 | ||
| DE2788 | 2016-02-29 | ||
| DP2639 | 2016-07-31 |